USDA Delays DEA-Required Marijuana Testing Due to 'Insufficient Capacity'

Dec.13.2022
USDA Delays DEA-Required Marijuana Testing Due to 'Insufficient Capacity'
USDA delays cannabis testing rule due to insufficient DEA-certified labs, worrying about lab capacity for 2023 growing season.

The United States Department of Agriculture (USDA) is delaying the implementation of a rule requiring marijuana to be tested by laboratories certified by the Drug Enforcement Administration (DEA). This is due to concerns over the "inadequate capabilities" of such facilities.


The US Department of Agriculture announced last week in a notice that it is extending the deadline for the enforcement of regulations on marijuana. The notice explains that the DEA laboratory testing requirements will not take effect as planned on January 1st. This controversial regulation is set to take effect on December 31, 2023, at the earliest.


The department stated that they are delaying the implementation of these requirements due to issues with the DEA laboratory registration process, as well as input from state and tribal governments and third-party cannabis testing facilities. Due to these delays, the USDA is concerned that there may not be enough cannabis laboratory testing capacity for the 2023 growing season, which could hinder the growth of the US cannabis market during this critical phase. It is important that laboratory testing of cannabis is in compliance with all other regulatory requirements.


Industry stakeholders in the United States have been criticizing the proposed requirement that only facilities registered with the DEA should conduct THC testing of marijuana. They argue that limited capacity has caused a bottleneck and that testing can be done effectively even without certification from the federal drug administration.


Earlier this year, Representative Chellie Pingree (D-ME) introduced a bill that would make multiple modifications to cannabis regulations, including the elimination of the requirement for DEA-registered labs to conduct testing.


US Agriculture Secretary Tom Vilsack has ultimately approved a broad federal rule that established regulations for the marijuana industry last year, despite concerns raised by advocates over certain provisions. This comes two years after the federal legalization of marijuana crops under the 2018 Agriculture Act.


Meanwhile, the United States Department of Agriculture is conducting an investigation to gather more information on cannabis production and the industry's economy.


At the same time, the agency also took measures to improve the insurance policies of cannabis businesses, making them more flexible in responding to stakeholder feedback.


2FIRSTS will continue to follow and report on this topic. Further updates will be available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.
Oct.21
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Singapore's Narcotics Bureau cracked down on a criminal group smuggling etomidate-containing e-cigarettes for the first time, arresting 8 people and seizing a large number of cartridges
Singapore's Narcotics Bureau cracked down on a criminal group smuggling etomidate-containing e-cigarettes for the first time, arresting 8 people and seizing a large number of cartridges
CNB launches first major operation against e-liquid smuggling group in Singapore, arresting 7 men and 1 woman.
Sep.15 by 2FIRSTS.ai
PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction
PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction
PMI Malaysia says Japan and New Zealand’s regulated smoke-free alternatives have hastened smoking declines, whereas Thailand’s post-2014 ban drives smokers to cigarettes or the black market—evidence, PMI argues, that pairing regulated alternatives with traditional controls could improve public health faster.
Oct.15 by 2FIRSTS.ai
2Firsts Connect @ InterTabac Concludes Successfully — Spotlight on Global Landscape, Market Shifts, and Future Opportunities
2Firsts Connect @ InterTabac Concludes Successfully — Spotlight on Global Landscape, Market Shifts, and Future Opportunities
2Firsts Connect @ InterTabac concluded successfully under the theme “From Change to Opportunity,” focusing on the global harm-reduction landscape, shifts in the U.S. market, dynamics in China’s supply chain, vaping product trends, and capital-market opportunities. 2Firsts International Editor-in-Chief Taco Tuinstra, compliance expert Kurt Yang, co-founder Echo Guo, and CEO Alan Zhao shared frontline insights, drawing on UK MHRA registration data and China customs export data to present a compreh
Sep.20
Reuters: FDA relaxes requirements for nicotine pouch pilot program, cancels special research on some products
Reuters: FDA relaxes requirements for nicotine pouch pilot program, cancels special research on some products
US FDA meeting minutes: Under Trump, a new pilot eases nicotine pouch rules—cuts product-specific research (uses generic data), shortens reviews, boosts communication. It’s the FDA’s first clear softer stance on smoking alternatives. The pilot may benefit Philip Morris (Zyn), Altria (On!), BAT (Velo) but sparks debate: FDA says pouches are low-risk (no youth surge), while ex-officials/academics cite missing research (hurts health checks, risks hidden youth use). Firms note costly research remain
Sep.19 by 2FIRSTS.ai